Navigation Links
ETEX Corporation Announces Distribution Agreement With Stryker
Date:7/14/2010

CAMBRIDGE, Mass., July 14 /PRNewswire/ -- ETEX Corporation, an advanced biomaterials company, announced today that it has entered into a non-exclusive distribution agreement with Stryker's Spine division to market and sell the privately labeled Bio MatrX Structure and Bio MatrX Generate bone graft substitute products. Both products utilize ETEX's proprietary nanocrystalline calcium phosphate technology, which is wholly owned, developed and exclusively manufactured by ETEX Corporation.

(Logo:  http://photos.prnewswire.com/prnh/20080424/NETH117LOGO  )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO )

BIO MatrX Structure is a highly porous, synthetic bone graft substitute that sets hard upon implantation for a complete defect fill. The resulting osteoconductive scaffold provides interconnected porosity and high surface area to facilitate cell mediated remodeling and new bone growth.

BIO MatrX Generate is a combination of ETEX's osteoconductive nanocrystalline calcium phosphate and Demineralized Bone Matrix (DBM) which is tested for osteoinductive potential by lot, after sterilization, in an in vivo athymic nude rodent muscle pouch model. The viscous putty sets hard after closure providing an osteoconductive scaffold to facilitate new bone growth.

Both materials are FDA cleared to be hydrated with saline or blood; and are indicated as bone void fillers of the pelvis, extremities and the posterolateral spine.

Brian Ennis, President and CEO of ETEX Corporation, comments: "ETEX Corporation is highly selective and discriminating in securing strategic partners. Stryker's Spine division possesses the desired distribution and marketing capabilities to increase exposure for ETEX's existing products and emerging technologies. The dynamic expansion of our distribution network is a direct reflection of the increasing market interest in our rapidly expanding product portfolio. We are pleased that Stryker has selected ETEX as its partner to complement their product offerings in the orthobiologic market segment."

About ETEX Corporation

Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.


'/>"/>
SOURCE ETEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Pharmos Corporation Reports 2008 Second Quarter Results
3. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
4. Genaera Corporation Announces Second Quarter Financial Results
5. MannKind Corporation Reports Second Quarter Financial Results
6. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
7. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. Mymetics Corporation Important Shareholders Information Conference Call
11. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma ... its innovative TransCon technology to address significant unmet ... results for the full year ended December 31, ... year for our company as we broadened our ... leading, integrated rare disease company with an initial ...
(Date:3/22/2017)... 22, 2017   iSpecimen ®, the ... Doctors Pathology Service (DPS), a full-service anatomic pathology ... the United States , has joined a program ... Network (DHIN) to make human biospecimens and associated ... novel program, announced in 2015 as a collaboration between ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017   ... of next-generation cancer therapeutics designed to target cancer stemness ... Patricia S. Andrews as Chief Executive Officer, ... will succeed Chiang J. Li , M.D., FACP, ... company ten years ago. Under his leadership, Boston Biomedical ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical ... desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is ... antibodies. , To meet this demand, the team at SCIEX has developed ...
Breaking Biology Technology:
(Date:2/28/2017)... February 28, 2017 News solutions for biometrics, ... ... from 14 to 16 March, Materna will present its ... how seamless travel is a real benefit for passengers. To ... to their passenger touch point solutions to take passengers through the ...
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
Breaking Biology News(10 mins):